The role of small vessel disease in development of Alzheimer's disease

Neural Regeneration Research

Volumn 5, Issue 4, 2010, Pages 310-320

  Grau Slevin, Marta ^a,b   Arboix, Adria ^b   Gaffney, John ^a   Slevin, Mark ^a  

^a MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Alzheimer's disease; Development; Diagnosis; Histopathological studies; Neural regeneration; Neurodegenerative disease; Neuroimaging studies; Risk factors; Small vessel disease

Indexed keywords

AGE DISTRIBUTION; ALZHEIMER DISEASE; ARTERIAL WALL THICKENING; ARTERIOLE; BASAL GANGLION; BLEEDING; BRAIN CAPILLARY; CAPSULA INTERNA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; DEMENTIA; DIABETES MELLITUS; DIFFUSION TENSOR IMAGING; DISEASE ASSOCIATION; DISEASE COURSE; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPOTENSION; MICROANGIOPATHY; MICROEMBOLISM; NEUROIMAGING; NEUROPATHOLOGY; PUTAMEN; REVIEW; RISK ASSESSMENT; THALAMUS; WHITE MATTER;

EID: 77949367148     PISSN: 16735374     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374     Document Type: Review

References (120)

1. Patterson C, Gauthier S, Bergman H. The recognition, assessment and management of dementing disorders: conclusions from the Canadian consensus conference on dementia. Can J Neurol Sci. 2001;28 Suppl 1:S3-16.
2. Henry-Feugeas MC. Alzheimer's disease in late-life dementia: A minor toxic consequence of devastating cerebrovascular dysfunction. Med Hypotheses. 2008;70:866-875.
3. Duron E, Hanon O. Hypertension, cognitive decline and dementia. Arch Cardiovasc Dis. 2008;101:181-189.
4. De la Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol. 2004;3:184-190.
5. Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997;277:813-817.
6. De la Torre JC. Alzheimer's disease is a vasocognopathy: a new term to describe its nature. Neurol Res. 2004;26:517-524.
7. st century. Neuroepidemiology. 2003;22: 161-164.
8. Erkinjuntti T, Pantoni L. Subcortical vascular dementia. In: Gauthier S, Cummings JL, eds. Yearbook of Alzheimer's Disease and Related Disorders. London, UK: Martin Dunitz. 2000;Chapter IX:101-133.
9. Werring DJ, Frazer DW, Coward LJ, et al. Cognitive dysfunction in patients with cerebral microbleeds on T2*-weighted gradient-echo MRI. Brain. 2004;127:2265-2275.
10. Fisher C. Lacunar strokes and infarcts: a review. Neurology. 1982;32:871-876.
11. Martí-Vilalta JL, Arboix A, Mohr JP. Lacunes. In: Mohr JP, Choi DW, Grotta JC, Weir B, Wolf PhA, eds. Stroke. Pathophysiology, diagnosis, and management. Philadelphia: Churchill Livingstone. 2004:275-299.
12. Sudlow CL, Warlow CP. Comparable studies of the incidence of stroke and its pathological types. Results from an international collaboration. Stroke. 1997;28:491-499.
13. Fisher CM. The arterial lesions underlying lacunes. Acta Neuropathol (Berl). 1969;12:1.
14. Chester EM, Agamanolis DP, Banker BQ, et al. Hypertensive encephalopathy: a clinicopathologic study of 20 cases. Neurology. 1978;28:928-939.
15. Baumgartner RW, Sidler C, Mosso M, et al. Ischemic lacunar stroke in patients with and without potential mechanisms other than small-artery disease. Stroke. 2003;34:653-659.
16. Fisher CM. Capsular infarcts: the underlying vascular lesions. Arch Neurol.1979;36:65-73.
17. nd ed. New York: Oxford University Press. 2002:47-66.
18. Mast H, Mohr JP. Binswanger's disease and vascular dementia. In: Mohr JP, Choi DW, Grotta JC, Weir B, Wolf PhA, eds. Stroke. Pathophysiology, Diagnosis, and Management. Philadelphia: Churchill Livingstone. 2004:679-686.
19. Vernooij MW, Ikram MA, Vrooman HA, et al. White matter microstructural integrity and cognitive function in a general elderly population. Arch Gen Psychiatry. 2009;66:545-553.
20. Pantoni L, García J. Pathogenesis of leukoaraiosis: a review. Stroke. 1997;28:652-659.
21. Sjöbeck M, Haglund M, Englund E. White matter mapping in Alzheimer's disease: A neuropathological study. Neurobiol Aging. 2006;27:673-680.
22. Kinoshita T, Okudera T, Tamura H, et al. Assessment of lacunar hemorrhage associated with hypertensive stroke by echo-planar gradient-echo T2*-weighted MRI. Stroke. 2000;31:1646-1650.
23. Han J, Gao P, Lin Y, et al. Three-tesla magnetic resonance imaging study of cerebral microbleeds in patients with ischemic stroke. Neurol Res. 2009;31(9):900-903.
24. Alemany M, Stenborg A, Terent A, et al. Co-existence of micro hemorrhages and acute spontaneous brain hemorrhage: correlation with signs of microangiopathy and clinical data. Radiology. 2006;238:240-247.
25. Wardlaw JM, Lewis SC, Keir SL, et al. Cerebral microbleeds are associated with lacunar stroke defined clinically and radiologically, independently of white matter lesions? Stroke. 2006;37: 2633-2636.
26. Pettersen JA, Sathiyamoorthy G, Gao FQ, et al. Microbleed topography, leukoaraiosis, and cognition in probable Alzhimer disease from the Sunnybrook dementia study. Arch Neurol. 2008;65:790-795.
27. Cordonnier C, van der Flier WM, Sluimer JD, et al. Prevalence and severity of microbleeds in a memory clinic setting. Neurology. 2006;66:1356-1360.
28. Fazekas F, Kleinert R, Roob G, et al. Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol. 1999;20:637-642.
29. Tanaka A, Ueno Y, Nakayama Y, et al. Small chronic hemorrhages and ischemic lesions in association with spontaneous intracerebral hematomas. Stroke. 1999;30:1637-1642.
30. Arboix A, Miguel M, Ciscar E, et al. Cardiovascular risk factors in patients aged 85 or older with ischemic stroke. Clin Neurol Neurosurg. 2006;108:638-643.
31. Berr C, Akbaraly TN, Nourashemi F, et al. Epidemiology of dementia. Presse Med. 2007;36:1431-1441.
32. Arboix A, Roig H, Rossich R, et al. Differences between hypertensive and non-hypertensive ischemic stroke. Eur J Neurol. 2004;11:687-692.
33. Jackson C, Sudlow C. Are lacunar strokes really different? A systematic review of differences in risk factor profiles between lacunar and nonlacunar infarcts. Stroke. 2005;36:891-901.
34. Besson G, Hommel M, Perret J. Risk factors for lacunar infarcts. Cerebrovasc Dis. 2000;10:387-390.
35. Helzner EP, Luchsinger JA, Scarmeas N, et al. Contribution of vascular risk factors to the progression in Alzheimer's disease. Arch Neurol. 2009;66:343-348.
36. Tzourio C. Hypertension, cognitive decline, and dementia: an epidemiological perspective. Dialogues Clin Neurosci. 2007;9:61-70.
37. Paglieri C, Bisbocci D, Caserta M, et al. Hypertension and cognitive function. Clin Exp Hypertens. 2008;30:701-710.
38. Aliev G, Seyidova D, Neal ML, et al. Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels as a central target for the development of human AD and AD-like pathology in aged transgenic mice. Ann NY Acad Sci. 2002;977:45-64.
39. De la Torre JC, Stefano GB. Evidence that Alzheimer's disease is a microvascular disorder: role of constitutive nitric oxide. Brain Res Rev. 2000;34:119-136.
40. Van Oijen M, de Jong FJ, Witteman JC, et al. Atherosclerosis and risk for dementia. Ann Neurol. 2007;61:403-410.
41. Waldstein SR, Rice SC, Thayer JF, et al. Pulse pressure and pulse wave velocity are related to cognitive decline in the Baltimore Longitudinal Study of Aging. Hypertension. 2008;51: 99-104.
42. Vagnucci AH Jr, Li WW. Alzheimer's disease and angiogenesis. Lancet. 2003;361:605-608.
43. Thomas T, Thomas G, McLendon C, et al. Beta-amyloid mediated vasoactivity and vascular endothelial damage. Nature. 1996;380: 168-171.
44. Bailey TL, Rivara CB, Rocher AB, et al. The nature and effects of cortical microvascular pathology in aging and Alzheimer's disease. Neurol Res. 2004;26:573-578.
45. Deane R, Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid-ß peptide transport across the blood-brain barrie rand accumulation in brain. Nat Med. 2003;9:907-913.
46. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 2005;28:202-208.
47. Hassing LB, Hofer SM, Nilsson SE, et al. Comorbid type 2 diabetes mellitus and hypertension exacerbates cognitive decline: evidence from a longitudinal study. Age Ageing. 2004;33:355-361.
48. Stewart R, Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet Med. 1999;16:93-112.
49. Thomas T, Thomas G, McLendon C, et al. Beta-amyloid-mediated vasoactivity and vascular endothelial damage. Nature. 1996;380: 168-171.
50. Young SE, Mainous AG, Carnemolla M. Hyperinsulinemia and cognitive decline in a middle-aged cohort. Diabetes Care. 2006;29:2688-2693.
51. Qiu WQ, Folstein MF. Insulin, insulin-degrading enzyme an amyloid beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol Aging. 2006;27:190-198.
52. Yaffe K, Kanaya A, Lindquist K, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA. 2004;292: 2237-2242.
53. Li YM, Dickson DW. Enhanced binding of advanced glycation endproducts (AGE) by the ApoE4 isoform links the mechanism of plaque deposition in Alzheimer's disease. Neurosci Lett. 1997;226: 155-158.
54. Blomqvist ME, Chalmers K, Andreasen N, et al. Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brain. Neurobiol Aging. 2005;26:795-802.
55. Fitzpatrick AL, Kuller LH, Lopez OL, et al. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol. 2009; 66:336-342.
56. Benoit SC, Clegg DJ, Seeley RJ, et al. Insulin and leptin as adiposity signals. Recent Prog Horm Res. 2004;59:267-285.
57. Kwon HM, Kim BJ, Lee SH, et al. Metabolic syndrome as an independent risk factor of silent brain infarction in healthy people. Stroke. 2006;37:466-470.
58. Panza F, Capurso C, D'Introno A, et al. Diet, cholesterol metabolism, and Alzheimer's disease: Apolipoprotein E as a possible link? J Am Geriatr Soc. 2006;54:1963-1965.
59. Reitz C, Tang MX, Luchsinger J, et al. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol. 2004;61: 705-714.
60. Kivipelto M, Helkala EL, Laakso MP, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002;137:149-155.
61. Simons M, Keller P, De Strooper B, et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Nat Acad Sci U S A. 1998;95:6460-6464.
62. Bodowitz S, Klein WL. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem. 1996;271: 4436-4440.
63. Pfrieger FW. Cholesterol homeostasis and function in neurons of the central nervous system. Cell Mol Life Sci. 2003;60:1158-1171.
64. Arvanitakis Z, Schneider JA, Wilson RS, et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology. 2008;70:1795-1802.
65. Haag MD, Hofman A, Koudstaal PJ, et al. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry. 2009;80: 13-17.
66. Boimel M, Grigoriadis N, Lourbopoulos A, et al. Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. J Neuropathol Exp Neurol. 2009;68:314-325.
67. Breteler MM. Vascular involvement in cognitive decline and dementia: epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan study. Ann NY Acad Sci. 2000;903:457-465.
68. Sabatini T, Frisoni GB, Barbisoni P, et al. Atrial fibrillation and cognitive disorders in older people. J Am Geriatr Soc. 2000;48: 387-390.
69. Rocchi A, Orsucci D, Tognoni G, et al. The role of vascular factors in late-onset sporadic Alzheimer's disease. Genetic and molecular aspects. Curr Alzheimer Res. 2009;6:224-237.
70. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325:1202.
71. Nakamizo T, Nagayama M. Stroke and the genetics of hyperhomocysteinemia. Brain Nerve. 2008;60:1295-1306.
72. Panza F, D'Introno, Colaccio AM, et al. Vascular risk and genetics of sporadic late-onset Alzheimer's disease. J Neural Transm. 2004;111:69-89.
73. Cedazo-Minguez A, Cowburn RF. Apolipoprotein E: a major piece in the Alzheimer's disease puzzle. J Cell Mol Med. 2001;5: 254-266.
74. Blacker D, Haines JL, Rodes L, et al. ApoE-4 gene at onset of Alzheimer's disease: the NIMH genetics initiative. Neurology. 1997;48:139-147.
75. Ma J, Yee A, Bryan Brewer Jr H, et al. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature. 1994;372:92-94.
76. Berr C, Hauw JJ, Delaere P, et al. Apolipoprotein E allele epsilon 4 is linked to increased deposition of the amyloid beta-peptide (A-beta) in cases with or without Alzheimer's disease. Neurosci Lett. 1994;178:221-224.
77. Frisoni GB, Govoni S, Geroldi C, et al. Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease. Ann Neurol. 1995;37:596-604.
78. Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA. 1995;273:1274-1278.
79. Growdon JH, Locascio JJ, Corkin S, et al. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology. 1996;47:444-448.
80. National Institute on Ageing/Alzhimer's Association Working Group. Apolipoprotein E genotyping in Alzheimer's disease. Lancet. 1996;347:1091-1095.
81. Folin M, Baiguera S, Guidolin D, et al. Apolipoproteion E modulates the cytotoxic effect of β-amyloid on rat brain endothelium in an isoform-dependent specific manner. Int J Mol Med. 2006;17:821-826.
82. Drouet B, Fifre A, Pincon-Raymond M, et al. ApoE protects cortical neurones against neurotoxicity induced by the non-fibrillar C-terminal domain of the amyloid-beta peptide. J Neurochem. 2001;76:117-127.
83. Granér M, Kahri J, Varpula M, et al. Apolipoprotein E polymorphism is associated with both carotid and coronary atherosclerosis in patients with coronary artery disease. Nutr Metab Cardiovasc Dis. 2008;18:271-277.
84. Utter S, Tamboli IY, Walter J, et al. Cerebral small vessel disease-induced apolipoprotein E leakage is associated with Alzheimer disease and the accumulation of amyloid beta-protein in perivascular astrocytes. J Neuropathol Exp Neurol. 2008;67:842-856.
85. Ruchoux MM, Brulin P, Leteurtre E, et al. Skin biopsy value and leukoaraiosis. Ann NY Acad Sci. 2000;903:285-292.
86. White RP, Deane C, Vallance P, et al. Nitric oxide synthase inhibition in humans reduces cerebral blood flow but not the hyperaemic response to hypercapnia. Stroke. 1998;29:467-472.
87. Sole-Padulles C, Bartres-Faz D, Junque C, et al. Poorer cognitive performance in humans with mild cognitive impairment carrying the T variant of the Glu/Asp NOS3 polymorphism. Neurosci Lett. 2004;358:5-8.
88. Lembo G, De Luca N, Battagli C, et al. A common variant of endotelial nitric oxide synthase [Glu298Asp] is an independent risk factor for carotid atherosclerosis. Stroke 2001;32:735-740.
89. Stenson PD, Ball EV, Mort M, et al. Human gene mutation database (HGMD): 2003 update. Hum Mutat. 2003;21:577-581.
90. Barden AE, Herbison CE, Beilin LJ, et al. Association between the endothelin-1 gene Lys198Asn polymorphism, blood pressure, and plasma endothelin-1 levels in normal and pre-eclamptic pregnancy. J Hypertens. 2001;19:1775-1782.
91. Asai T, Ohkubo T, Katsuya T, et al. Endothelin-1 gene variant associates with blood pressure in obese Japanese subjects: the Ohasama Study. Hypertension. 2001;38:1321-1324.
92. Gormley K, Bevan S, Markus HS. Polymorphisms in genes of the renin-angiotensin system and cerebral small vessel disease. Cerebrovasc Dis. 2007;23:148-155.
93. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet. 2003;35:131-138.
94. De la Torre JC. Cerebrovascular gene linked to Alzheimer's disease pathology. Trends in Mol Med. 2005;11:534-536.
95. Wu Z, Guo H, Chow N, et al. Role of the MEOX2 homebox gene in neurovascular dysfunction in Alzheimer's disease. Nat Med. 2005;11:959-965.
96. De Groot JC, De Leeuw FE, Oudkerk M, et al. Cerebral white matter lesions and cognitive function: The Rotterdam Scan Study. Ann Neurol 2000;47:145-151.
97. Burton EJ, Ballard C, Stephens S, et al. Hyperintensities and fronto-subcortical atrophy on MRI are substrates of mild cognitive deficits after stroke. Dement Geriatr Cogn Disord. 2003;16: 113-118.
98. Wu CC, Mungas D, Petkov CI, et al. Brain structure and cognition in a community sample of elderly latinos. Neurology. 2002;59: 383-391.
99. De Leeuw FE, Barkhof F, Scheltens P. White matter lesions and hippocampal atrophy in Alzheimer's disease. Neurology. 2004;62: 310-312.
100. Rosano C, Aizenstein HJ, Wu M, et al. Focal atrophy and cerebrovascular disease increase dementia risk among cognitively normal older adults. J Neuroimaging. 2007;17: 148-155.
101. Fein G, Di Sclafani V, Tanabe J, et al. Hippocampal and cortical atrophy predict dementia in subcortical ischemic vascular disease. Neurology. 2000;55:1626-1635.
102. O'Brien JT, Paling S, Barber R, et al. Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology. 2001;56:1386-1388.
103. Johnson KA, Albert MS. Perfusion abnormalities in prodromal Alzheimer's disease. Neurobiol Aging. 2000;21:289-292.
104. Kogure D, Matsuda H, Ohnishi T, et al. Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT. J Nucl Med. 2000;41:1155-1162.
105. Okamura N, Shinkawa M, Arai H, et al. Prediction of progression in patients with mild cognitive impairment using IMP-SPECT. Nippon Ronen Igakkai Zasshi. 2000;37:974-978.
106. Rodriguez G, Vitali P, Calvini P, et al. Hippocampal perfusion in mild cognitive impairment. Psychiatry Res. 2000;100:65-74.
107. Englund E, Sjöbeck M, Brockstedt S, et al. Diffusion tensor MRI post mortem demonstrated cerebral white matter pathology. J Neurol. 2004;251:350-352.
108. Bozzali M, Falini A, Franceschi M, et al. White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging. J Neurol Neurosurg Psychiatry. 2002;72:742-746.
109. Sjöbeck M, Englund E. Glial levels determine severity of white matter disease in Alzheimer's disease-A neuropathological study of glial changes. Neuropathol Appl Neurobiol. 2003;29:159-169.
110. Ringelstein EB, Nabavi DG. Cerebral small vessel diseases: cerebral microangiopathies. Curr Opin Neurol. 2005;18:179-188.
111. Meyer EP, Ulmann-Schuler A, Staufenbiel M, et al. Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease. Proc Natl Acad Sci U S A. 2008; 105:3587-3592.
112. Patel NS, Quadros A, Brem S, et al. Potent anti-angiogenic motifs within the Alzheimer beta-amyloid peptide. Amyloid. 2008;15: 5-19.
113. Aliev G, Gasimov E, Obrenovich ME, et al. Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels: Implication in the patogenesis of Alzheimer's disease. Vasc Health Risk Manag 2008;4:721-730.
114. Cullen K, Koszi Z, Stone J. Microvascular pathology in the aging human brain: evidence that senile plaques are sites of microhaemorrhages. Neurobiol Aging. 2006;27:1786-1796.
115. Cullen K, Kocsi Z, Stone J. Pericapillary haem-rich deposits: evidence for microhaemorrhages in aging human cerebral cortex. J Cereb Blood Flow Metab. 2005;25:1656-1667.
116. Zekry D, Duyckaerts C, Moulias R, et al. Degenerative and vascular lesions of the brain have synergistic effects in dementia of the elderly. Acta Neuropathol. 2002;103:481-487.
117. Marlatt MW, Lucassen PJ, Perry G, et al. Alzheimer's disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies. J Alzheimers Dis. 2008;15:199-210.
118. Torrente Y, Polli E. Mesenchymal stem cell transplantation for neurodegenerative diseases. Cell Transplant. 2008;17:1103-1113.
119. Lange-Asschenfeldt C, Kojda G. Alzheimer's disease, cerebrovascular dysfunction and the benefits of exercise: from vessels to neurons. Exp Gerontol. 2008;43:499-504.
120. Van der Flier WM, Barkhof F, Scheltens P. Shifting paradigms in dementia: Toward stratification of diagnosis and treatment using MRI. Ann NY Acad Sci. 2007;1097:215-224.